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 Abstract 
Main objectives to develop Aceclofenac Nanosuspension are to enhance solubility and dissolution rate of poorly 
soluble Drug (Aceclofenac), substantially leading to its bioavailability enhancement &Improvement of aqueous and 
saturation solubility in turn rapid release of Drug which leads to enhancing therapeutic efficacy. Aceclofenac 
Nanosuspension was prepared by quasi solvent evaporation method with help of different polymer and concentration. There 
was changes polymer ratio, volume of organic solvent and stirring speed. Aceclofenac nanosuspension gives immediate 
release. Aceclofenac nanosuspension were showing highest dissolution rate within 10 minutes comparison with marketed 
formulations. Aceclofenac Nanosuspension compacts may enhance aqueous solubility and dissolution rate in compare to 
other solubility enhancement technique hence, this research work may be useful to formulate Aceclofenac Nanosuspension 
which may give rapid onset of action by rapid absorption, maximize efficacy, dose frequency & hence increase patient 
Compliance.  
Keywords: Aceclofenac, Nanosuspension, solubility enhancement, dissolution enhancement. 
1. Introduction  
Method by which solution is passing on can 
essentially influence its feasibility. Some drug has perfect 
obsession range inside most compelling favourable 
position. On other hand, moderate progression in ampleness 
of treatment of couple diseases, and suggested growing 
need of multidisciplinary approach to manage movement of 
therapeutics to center in tissue. From this new thought to 
controlling pharmacokinetics, pharmacodynamic, non-
specific destructiveness, immunogenicity to be made. This 
new thought called as novel solution transport system. In it 
is planned to achieve reliable movement of pharmaceutical 
at obvious and reproducible vitality over opened up time 
span accessible for use. Blend of bolstered release and 
controlled release property in movement structure would 
encourage improve remedial effigy. 
1.2 Introduction to Nanotechnology 
Nanotechnology is craft of matter and material that 
game plan with particle size in nanometres. "Nano" is 
gotten from Latin word, which suggests diminutive person 
(1nm=10
-9
m). Nanomedicine oversees extensive checking, 
control, improvement, and repair, monitor and upgrade 
human natural structure at nuclear level using outlined 
nanostructures and Nano devices. Pharmaceutical 
Harshil M Patel et al / Formulation and Development of Nanosuspension of Aceclofenac                                                                          34 
IJAP (2018) 07 (05)                                                                                                                                          www.ssjournals.com 
nanotechnology handles employments of nanoscience to 
medication store as nanomaterials, and as devices like 
medicine movement, decisive, imaging and biosensor 
materials. Pharmaceutical nanotechnology has given all 
more balanced conclusion and focused treatment of ailment 
at sub-nuclear level. It helps in perceiving antigen 
associated with diseases, for instance, harm, diabetes 
mellitus, neurodegenerative sicknesses, and likewise 
distinguishing microorganisms and disease associated with 
pollutions. In medication store size decline has crucial 
application as prescriptions in nanometre size achieve 
overhaul execution in arrangement of estimations 
structures.  
Nanotechnology gives number of positive 
circumstances in medication store by;  
1) Extended surface locale  
2) Enhanced dissolvability  
3) Extended rate of crumbling  
4) Extended in oral bioavailability  
5) Less measure of dose required and lessens amount of 
doses  
6) Protection of prescription from corruption  
7) All quicker onset of medicinal action  
8) Achievement of prescription concentrating on  
9) Latent centering of drugs to macrophages present in 
liver and spleen.  
Diverse sorts of DDS using Nanotechnology 
Principle:  
1) Nanosuspension  
2) Solid lipid nanosuspensions  
3) Nanocrystals  
4) Nanosuspensions  
5) Nanoemulsion 
1.3 Introduction to Nanosuspension: 
Pharmaceutical Nanosuspension is portrayed as 
finely scattered solid drug particles in liquid vehicle. Atom 
size in Nanosuspension extends some place around 200 and 
600nm. Scrambling of drug Nanocrystals in liquid media 
prompts "Nanosuspension". Scrambling media can be 
water, liquid plans or non-watery media (e.g., liquid 
polyethylene glycol (PEG), oils).  
Nanosuspensions have positive circumstances of:  
1) Increase in crumbling pace and drenching dissolvability 
of medicine  
2) Improved natural execution  
3) Ease of creation and scale-up  
4) Long-term physical soundness  
5) Versatility  
6) Increase in oral absorption  
7) Improved dose proportionality [1-2] 
1.3.1 Method of Nanosuspensions
 
Basically there are two methods for course of 
action of Nanosuspensions. Customary procedures for 
precipitation (Hydrosols) are called 'Base up 
development'.'Top down Technologies' are separating 
methodologies and are favored over precipitation 
strategies. ‘Top down Technologies' fuse Media Milling 
(Nanocrystals), High Pressure Homogenization in water 
(Disso cubes), High Pressure Homogenization in non-
watery media (Nano pure) and mix of Precipitation and 
High-Pressure Homogenization (Nanodegree).  
1) Bottom-up advancement  
2) Top-down advancement 
1.4 Formulation Consideration 
1.4.1 Stabilizer 
Essential limit of stabilizer is to wet prescription 
particles totally, and to keep Ostwald’s developing and 
agglomeration of Nanosuspensions with particular finished 
objective to yield physically stable arrangement by giving 
steric or ionic deterrent. Sort and apportion of parity 
pronouncedly influences physical strength and in vivo 
behavior of Nanosuspension. Stabilizers that have been 
used so far are poloxamer, polysorbate, cellulosic, 
procurements, and lecithin. Lecithin is stabilizer of choice 
if one intends to develop parentally commendable and 
auto-clavable Nanosuspension. 
1.4.2 Organic Solvent 
Characteristic solvents are used as part of 
arrangement of Nanosuspension if emulsions or littler scale 
emulsions are used as organization. pharmaceutically 
acceptable less risky water miscible dissolvable, for 
instance, methanol, ethanol, chloroform, isopropanol, and 
generally water miscible solvents ethyl acidic corrosive 
deduction, ethyl format, butyl lactate, triacetin, propylene 
carbonate, benzyl alcohol are height in arrangement over 
conventional dangerous solvents, for instance, 
dichloromethane. 
1.4.3 Co-Surfactants 
Choice of co-surfactant is fundamental while 
using littler scale emulsions to characterize 
Nanosuspensions. Since co-surfactants can extraordinarily 
affect stage direct effect of co-surfactant on uptake of 
internal stage for picked scaled down scale emulsion course 
of action and taking drugs stacking should be investigated. 
In spite of way that written work depicts use of bile salts 
and dipotassium glycerrhizinate as co-surfactants, 
distinctive solubilizes, for instance, Transcutol, glycofurol, 
ethanol and isopropanol, can be safely used as co-
surfactants as part of enumerating of scaled down scale 
emulsions. 
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1.4.4 Other additives 
Nanosuspensions may contain included 
substances, for instance, supports, salts, polyols, osmogent 
and Cryoprotectant. 
1.5 Post-Production Processing 
After era treatment of Nanosuspensions gets 
opportunity to be key when drug contender is exceptionally 
defenseless to hydrolytic cleavage or compound corruption. 
Taking care of may in like manner is required when best 
stabilizer is not prepared to offset Nanosuspension for more 
drawn out time period or there are pleasantness 
impediments concerning fancied course. Considering these 
perspectives, techniques, for instance, lyophilisation or 
sprinkle drying may be used to make dry powder of Nano-
sized prescription particles. Sound decision must be made 
in these unit operations considering pharmaceutical 
properties and monetary points. Generally, shower drying 
is more calm and accommodating than Lyophilization. 
Effect of postproduction planning on particle size of 
Nanosuspension and suddenness substance of dried nano 
measured drug should be given due thought.[3-10] 
1.6 Applications of Nanosuspension 
1.6.1 Oral 
Oral pharmaceutical movement is most 
comprehensively supported course of association of meds. 
In any case, couple of meds has issue of compelled 
bioavailability as result of poor dissolvability and 
absorption which finally reduces its sufficiency. In such 
cases, Nanosuspension can deal with issue as it associates 
in improving deterioration rate and ingestion in light of 
extended surface range and updated adhesiveness. 
Nanosuspension can provoke extended mucoadhesion 
which can increase gastrointestinal travel time and incite 
extended bioavailability. Redesign in oral bioavailability 
can be credited to extended surface zone, drenching 
dissolvability and adhesiveness of solution 
Nanosuspension. Taste covering of particulate structure is 
moreover successfully possible. 
1.6.2 Parenteral 
Nanosuspensions can be used to change 
ineffectually dissolvable non-injectable meds into 
definition suitable for intravenous association. 
Notwithstanding way that production of Nanosuspension 
for parenteral use is fundamental, current headways in this 
development have shown its utility as injectable 
definitions. Strategies used for availability of Nano-
suspension are as of now precisely controlled, and can 
make uniform particles with better control over most great 
atom size. Distinctive examination reports are open which 
stretch fittingness of Nanosuspensions for parenteral 
association. 
1.6.3 Ocular delivery 
Nanosuspension can wind up being safe house for 
solutions that show poor dissolvability in lachrymal fluids. 
Nanosuspensions address flawless strategy for visual 
movement of hydrophobic solutions in light of their natural 
ability to upgrade drenching dissolvability of prescriptions. 
Kassem et al have made Nanosuspension transport 
structure for certain glucocorticoid drugs. 
1.6.4 Pulmonary 
Nanosuspensions can be beneficial for passing on 
sedates that show poor dissolvability in pneumonic 
discharge. At present open procedures for aspiratory 
movement, for instance, pressurized canned items or dry 
powder inhalers have certain deterrents, for instance, 
compelled spread at required site, less living plan time et 
cetera, which can be overcome by Nanosuspensions. 
Fluticasone and budesonide have been successfully nitty 
gritty as Nanosuspension for aspiratory Delivery  
1.6.5 Dermal 
Nano-crystalline structure has extended drenching 
dissolvability achieving redesigned dispersal of medicine 
into skin. Nanocrystals also indicate distinctive properties, 
for instance, extended penetration into film, overhauled 
pervasion and bio-adhesiveness which could be to great 
degree accommodating for dermal application. 
1.6.6 Targeting 
Uptake of pharmaceutical nanosuspensions 
depends on upon their atom size. By changing surface 
properties of nanosuspensions, their in vivo behavior can be 
balanced and can be used as engaged transport system. 
phagocytosis uptake of nano-valuable stones can be 
avoided by preparing stealth nanocrystals or by arranging 
keen pearls i.e. drug particles underneath atom size of 
100nm, which can be used as concentrated taking drugs 
movement structure. In light of methodology ease, change 
of nanosuspension is mechanically suitable decision for 
cantered transport. Surface properties of particles, for 
instance, surface hydrophobicity, charge, closeness and 
centralization of certain valuable social occasions choose its 
organ flow. Atovaquone nano-valuable stones secured with 
Tween 80 were used to treat toxoplasmosis; parasites could 
be successfully pulverized in cerebrum. 
1.7 Mucoadhesion of Nanosuspensions 
Nanosuspensions orally controlled as suspension 
diffuse into liquid media and rapidly encounter mucosal 
surface. Particles are immobilized at intestinal surface by 
hold framework insinuated as "bio connection." From this 
moment on concentrated suspension goes about as supply 
of particles and adsorption process happens rapidly. Prompt 
contact of particles with intestinal cells through bio-paste 
stage is underlying stride before atom ingestion.[11-15] 
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1.8 Marketed products 
Table: 1 Marketed products of Nanosuspension 
Product Drug Indication Company 
Triglide Fenofibrae Treatment of hypercholesterolemia Firsthorizon pharmaceutical 
Tricor Fenofibrae Treatment of hypercholesterolemia Abbott 
MEgace Megestrol Aceyate Appetite Stimulant PAR Pharmaceutical 
Rapamune Sirolims Immunosuppress Wyeth 
 
2. Materials and methods 
Aceclofenac was received as a gift sample from 
Torrent Pharmaceutical Ltd., Ahmedabad. PVA, PVP K-30, 
Tween-80 & Acetone were received as a gift sample from 
Laboratory Sulab Reagent, Vadodara. Pluronic F68 was 
received as a gift sample from Colorcon Pt. Ltd., Goa.  
2.1 Method of Preparation of Aceclofenac 
Nanosuspension 
Nanosuspensions were prepared by Quasi- 
Emulsion Solvent Evaporation Method. Aceclofenac was 
dissolved in acetone at room temperature. This was poured 
into fixed amount of water containing fixed amount of 
different stabilizers at room temperature and subsequently 
stirred on magnetic stirrer to allow volatile solvent to 
evaporate (Remi, magnetic stirrer, India). Addition of 
organic solvents by means of syringe positioned with 
needle directly into stabilizer containing water. Organic 
solvents were left to evaporate off under slow magnetic 
stirring of Nanosuspension at room temperature for 1 
hour.[39] 
2.2 Characterization of Aceclofenac Nanosuspension 
2.2.1 Particle size 
Particle size was determined by photon correlation 
spectroscopy (PCS) using Zetasizer 3000 (Malvern 
Instruments, UK). This analysis yields mean diameter (z-
average, measuring range: 20–1000 nm). All data presented 
are mean values of three independent samples produced 
under identical production conditions. 
2.2.2 Drug content 
Prepared Nanosuspensions was analyzed for drug 
content by UV spectroscopic method. Different batches of 
nanosuspensions equivalent to 20 mg of Aceclofenac 
weighed accurately and dissolve in 10 ml acetone. Stock 
solutions will be diluted with distilled water and analyze by 
UV spectroscopy at 275 nm. 
2.2.3 Saturation solubility studies 
Saturation solubility measurements were analyzed 
by ultraviolet absorbance determination at 275 nm using 
Shimadzu UV-Visible spectrophotometer. Saturation 
solubility studies will be carried out for both unprocessed 
pure drug and different batches of lyophilize 
Nanosuspension. 10 mg of unprocessed pure drug and 
Nanosuspension equivalent to 10 mg of Aceclofenac will be 
weighed and separately introduce into 25 ml stoppered 
conical flask containing 10 ml distilled water. Flasks will be 
seal and place in rotary shaker for 24 hrs at 37°C and 
equilibrate for 2 days. Samples will be collect after specific 
time interval, and it is filter and analyze. Dilute samples 
was analysed using UV spectrophotometer at 238 nm. 
Results were analyzed in triplicate and standard deviations 
are report. 
 
2.3 In vitro Drug Release Study 
Table: 2 In-vitro drug release study 
Instrument USP Dissolution apparatus 
Type Paddle method 
Medium 900 ml Phosphate buffer pH 7.4 
Temperature 37± 0.5ºC 
RPM 50 
Testing time 60 min 
Amount withdrawn 5 ml 
Λ max 275 nm 
Sample Nanosuspensions 
Sample Withdrawal 
interval 
Every 5 Min 
 
2.4 Stability Analysis 
Drug or dosage form quality may affect under 
impact of by varying temperature, humidity and light with 
time which can be found out by stability testing. It can be 
carried out at 25°C ± 2°C/ 60% RH ± 5% RH and 40°C ± 
2°C/ 75% RH ± 5% RH for selected formulation for three 
months. Samples were withdrawn on 0
th
, 10
th
, 20
th
 and 30
th
 
day and were analyzed for physical appearance and drug 
content.[34,39,40] 
 
3. Result and Discussion 
3.1 Solubility study of Aceclofenac 
Aqueous solubility of Aceclofenac in powder form 
was determined by shake-flask method. Briefly, 20mg of 
Aceclofenac was suspended in 10ml of water; and 
suspensions were shaken at 37°C. Aliquots were withdrawn 
and filtered through0.22µm Whatmen filter. Filtered 
solution was suitably diluted and Aceclofenac concentration 
infiltrate was analyzed by UV analysis method at 275nm 
(Systronic 2203, Japan).  For other solvents such as acetate 
buffer, phosphate buffer, HCl, acetone, methanol same 
procedure was followed. 
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Table 1: Solubility of aceclofenac in various surfactant 
and co-surfactant 
Solvents 
Solubility  
(mg/10 ml) 
(Mean ± S.D.)  
(n = 3) 
Interpretation 
Distilled Water 0.0079±0.08 
Very Slightly 
soluble 
pH 4.5 Acetate 
Buffer 
0.131±0.14 Slightly soluble 
pH 6.8 Phosphate 
Buffer 
2.51±0.15 Soluble 
pH 7.4 Phosphate 
Buffer 
4.019±0.07 Soluble 
0.1NHCL 0.039±0.25 Slightly soluble 
Acetone 9.78±0.012 Freely  soluble 
Ethanol 8.48±0.079 Freely soluble 
 
Aceclofenac was completely dissolved in Acetone 
and slightly dissolved in Water. 
 
3.2 Identification of Drug- Aceclofenac by FT-IR 
Spectroscopy 
Fourier–transform infrared (FT–IR) spectra of 
moisture free powdered samples of SS, its lyophilized 
nanosuspensions and PVPK-30 were obtained using 
spectrophotometer (FTIR- Shimadzu Co., Kyoto, Japan) by 
potassium bromide (KBr) pellet method. Scanning range 
was 400–4000 cm-1 and resolution was 1 cm-1. 
 
 
Figure 1: Identification of Pure Drug Aceclofenac + PVP + Tween 80 by IR Spectrum 
 
3.3 Drug Compatibility Studies by DSC 
DSC curves of commercial Aceclofenac Figure 5.4 
shows broad endotherm ranging from 30 to 120°C 
indicating loss of water and sharp endotherm at 156.46 °C 
might be due to melting point of Aceclofenac. Obtained FT-
IR spectrum and DSC graph compiles with standard data 
which further confirms identity and purity of Drug. 
 
 
Figure 2: Drug Compatibility Studies by DSC 
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3.4 Preliminary Selection of Stabilizer Concentration 
Table 4: Preliminary Selection of Stabilizer Concentration for Aceclofenac Nanosuspension 
Batch Type of Stabilizer 
Stabilizer 
Concentration 
Type of Organic 
Phase (mL) 
Volume of Organic 
Phase (mL) 
Stirring Speed 
(R.P.M.) 
Preliminary selection of concentration of stabilizers 
ANS1 Pluronic F- 68: Tween 80 2:1 Acetone 5 1500 
ANS2 Pluronic F- 68: Tween 80 3:1 Acetone 5 1500 
ANS3 Pluronic F- 68: Tween 80 4:1 Acetone 5 1500 
ANS4 PVP K30: Tween 80 2:1 Acetone 5 1500 
ANS5 PVP K30: Tween 80 3:1 Acetone 5 1500 
ANS6 PVP K30: Tween 80 4:1 Acetone 5 1500 
  
Table 5: Characterization of Trial batches (ANS1 – ANS6) for Aceclofenac NSs 
Batch 
No. 
Drug Content (mg) 
(Mean± S.D.) (n=3) 
Entrapment Efficiency 
(%) (Mean±S.D.) (n=3) 
Free Drug Content 
(%) 
% CDR 
(Mean ±S.D.) (n=3) 
Preliminary selection of stabilizer concentration 
ANS1 15.704±0.26 70.52±1.41 29.48 78.26±0.43 
ANS2 17.478±0.56 79.41±1.59 20.59 85.98±0.69 
ANS3 18.042±0.42 82.21±1.39 17.79 92.54±0.53 
ANS4 11.178±0.29 47.89±1.51 52.11 75.25±0.42 
ANS5 13.646±0.41 60.23±1.35 39.77 81.69±0.54 
ANS6 12.468±0.27 54.34±1.24 45.66 86.27±0.38 
 
Nanoparticulate DDS regularly utilize stabilizers. 
Without suitable stabilizer, high surface vitality of particles 
in nano-reach can total to shape bigger particles, along 
these lines rendering definition shaky. Primary capacity of 
stabilizer is to wet medication molecule totally to repress 
agglomeration with another molecule. It gives stearic or 
ionic boundaries by method for which between particulate 
associations in nanosuspensions are counteracted. Be that as 
it may, convergence of stabilizer in Nanosuspension must 
be ideal. PVA has been observed to be extremely successful 
stabilizer for Nanoparticles created by different techniques. 
PVA or Polyvinyl Alcohol has both hydrophobic and 
hydrophilic parts compare acetic acid derivation and 
hydroxyl bunches separately. These assistance in getting 
retained and arranged at interface. Truth be told, viability of 
PVA in lessening interfacial strain is such that it even 
elevates to keeping up low molecule size of Nanoparticles. 
Indeed, even surfactants like Pluronic F-68 and Tween 80 
have been used for decreasing interfacial pressure at surface 
of nanoparticles. Thus, ANS 2 and ANS3 have been chosen 
as improved clusters.  
 
3.5 Preliminary Selection of Organic Solvent Volume 
Table 6: Preliminary Selection of Organic Solvent Volume for Aceclofenac Nanosuspension 
Batch Type of Stabilizer 
Stabilizer 
Concentration 
Type of Organic 
Phase (mL) 
Volume of Organic 
Phase (mL) 
Stirring Speed 
(R.P.M.) 
Preliminary selection of organic phase volume 
ANS7 Pluronic F- 68: Tween 80 3:1 Acetone 5 1500 
ANS8 Pluronic F- 68: Tween 80 3:1 Acetone 10 1500 
ANS9 Pluronic F- 68: Tween 80 3:1 Acetone 20 1500 
  
Table 7: Characterization of Trial batches (ANS7 – ANS9) for Aceclofenac Nanosuspension 
Batch 
No. 
Drug Content (mg) 
(Mean± S.D.) (n=3) 
Entrapment Efficiency 
(%) (Mean±S.D.) (n=3) 
Free Drug Content 
(%) 
% CDR 
(Mean ±S.D.) (n=3) 
Effect of organic phase volume 
ANS7 16.446±0.48 72.23±1.33 27.77 86.57±0.38 
ANS8 16.908±0.32 74.54±1.21 25.46 89.68±0.62 
ANS9 13.476±0.36 67.38±1.56 32.62 88.17±0.48 
 
Natural solvents are regularly utilized in definition 
of nanoparticles by assortment of strategies. Nonetheless, 
since numerous natural chemicals can be risky in nature, 
adequacy of natural dissolvable being utilized in detailing 
must be remembered as for its poisonous quality potential 
and simplicity of its expulsion from plan. Solvents, for 
example, ethanol, isopropanol, ethyl acetic acid derivation, 
butyl lactate, CH3)2CO, and triacetin and benzyl liquor are 
some which are thought to be satisfactory and accordingly 
utilized in definition. Thus, ANS 8 has been chosen as 
enhanced cluster. One of most essential things to be 
remembered while using natural solvents is their miscibility 
with water. More dissolvable is miscible and promptly 
diffusible with water, more compelling will be development 
of nanosuspension. 
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3.6 Preliminary Selection of Stirring Speed (RPM) 
Table 8: Preliminary Selection of Speed (RPM) for Aceclofenac Nanosuspension 
Batch Type of Stabilizer 
Stabilizer 
Concentration 
Type of Organic 
Phase  (mL) 
Volume of Organic 
Phase  (mL) 
Stirring Speed 
(R.P.M.) 
Preliminary selection of speed (R.P.M.) 
ANS10 Pluronic F- 68: Tween 80 3:1 Acetone 5 1000 
ANS11 Pluronic F- 68: Tween 80 3:1 Acetone 5 1500 
ANS12 Pluronic F- 68: Tween 80 3:1 Acetone 5 2000 
 
Table 9: Characterization of Trial batches (ANS10 – ANS12) for Aceclofenac Nanosuspension 
Batch No. 
Drug Content (mg) 
(Mean±S.D.) (n=3) 
Entrapment efficiency 
(%) (Mean±S.D.) (n=3) 
Free Drug Content 
(%) 
%CDR 
(Mean±S.D.) (n=3) 
Selection of speed 
ANS10 17.124±0.56 77.62±1.28 22.38 87.69±1.35 
ANS11 18.444±0.48 84.22±1.37 15.78 90.87±1.42 
ANS12 17.64±0.36 80.23±1.31 19.77 91.87±1.48 
 
Stirring speed is also important formulation 
variable. It has been observed that on average, increasing 
speed of stirring leads to reduction in particle size towards 
Nano sized range. However, it has been noted that 
operating instruments at high speed conditions is not 
always optimum and average speed has to be maintained. 
This is because higher agitation speeds often lead to 
formation of huge amount of foam in suspension which 
often leads to early separation of solid nanoparticles from 
aqueous medium. As result, this can lead to ineffective size 
reduction and insufficient formation of Nanosuspension. 
Hence, ANS 11 and ANS 12 have been selected as 
optimized batches. 
3.7 3
2
 Factorial Design Approach 
Table 10: 3
2 
Factorial Design 
Independent Variables of Formulations 
Independent Variables 
Low  
(-1) 
Medium 
(0) 
High 
(+) 
Stabilizer 
Concentration (X10 
2:1 3:1 4:1 
Speed (RPM)(X2) 1000 1500 2000 
Dependent Variables 
Y1= % Entrapment Efficiency 
Y2= %CDR 
3.8 Compositions of Factorial Batches in decoded Form 
Table 11: Compositions of Factorial Batches in Coded 
Form 
ACE NS 32=9 Batches 
Variable level in decoded form 
Batch No 
Stabilizer 
Concentration(X1) 
Speed (R.P.M.) 
(X2) 
ACNS1 -1 -1 
ACNS2 -1 0 
ACNS3 -1 +1 
ACNS4 0 -1 
ACNS5 0 0 
ACNS6 0 +1 
ACNS7 +1 -1 
ACNS8 +1 0 
ACNS9 +1 +1 
3.9 Formulation Design by 3
2
 Factorial Designs 
Table12: Formulation Design by 3
2
 Factorial Design 
Aceclofenac NS 32=9 Batches 
Variable level in decoded form 
Batch No Stabilizer Concentration(X1) 
Speed (R.P.M.) 
(X2) 
ACNS1 2:1 1000 
ACNS2 2:1 1500 
ACNS3 2:1 2000 
ACNS4 3:1 1000 
ACNS5 3:1 1500 
ACNS6 3:1 2000 
ACNS7 4:1 1000 
ACNS8 4:1 1500 
ACNS9 4:1 2000 
   
 
Figure 3: Various Aceclofenac loaded Nanosuspension 
formulation using by 3
2
 Factorial Designs 
 
3.10 Characterization of Batches (ACNS1-ACNS9) 
Table 13: Characterization of Batches (ACNS1 to 
ACNS9) 
Batch No Entrapment Efficiency (%) Drug release (%) 
ACNS1 81.70±0.59 90.74±0.26 
ACNS2 76.25±.0.72 85.69±0.36 
ACNS3 75.55±0.42 84.71±0.42 
ACNS4 80.82±0.56 89.29±0.34 
ACNS5 85.45±0.68 92.37±0.39 
ACNS6 72.98±0.69 82.13±0.40 
ACNS7 79.80±0.73 88.28±0.24 
ACNS8 77.59±0.86 86.26±0.37 
ACNS9 86.14±0.55 93.42±0.42 
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3.11 Saturation solubility studies 
Table: 14 Characterization of Saturation 
Solubility of Batches (ACNS1 to ACNS9) 
Batch No Saturation Solubility 
ACNS1 189.20±0.15 
ACNS2 186.62±0.22 
ACNS3 196.72±0.27 
ACNS4 179.58±0.12 
ACNS5 180.43±0.28 
ACNS6 202.64±0.26 
ACNS7 192.30±0.27 
ACNS8 192.83±0.12 
ACNS9 192.55±0.20 
3.12 Statistical Analysis 
Plan master programming rendition 9.0.2.0. Was 
utilized for Statistical investigation and delivered first 
request polynomial mathematical statements. From 
preparatory results, 32 full factorial configuration was used 
in which two elements were assessed, independently at 
three levels and conceivable nine mixes were planned. 
Three level factorial studies were done utilizing two 
distinct variables. In first factorial outline, measure of 
Stabilizer focus (X1) and Speed (X2) were taken as free 
variables while % E.E (Y1), % CDR (Y2) and immersion 
dissolvability were chosen as needy variables for both 
factorial plans. 
3.13 Effect on Entrapment Efficiency (Y1) - Surface 
Response Study 
Positive quality for coefficient of X1-sort of 
stabilizer fixation in mathematical statement shows 
increment in Entrapment Efficiency. Positive estimation of 
coefficient of X2-Speed shows increment accordingly of 
Y1 i.e. Entanglement Efficiency. It demonstrates linearity 
of surface reaction and shape plot as appeared in figure. 
Full model was discovered immaterial so lessened model 
was connected for each of the two autonomous variables 
and definite ANOVA, Response Surface Counter Plot and 
3 D plot are as per the following: 
Y=+79.00+2.83* A+4.33* B 
 
Table 15: ANOVA Table for Response Y1 (Entrapment Efficacy) 
ANOVA for Response Surface Linear model 
Analysis of variance table [Partial sum of squares - Type III] 
 
Sum of 
 
Mean F p-value 
 
Source Squares Df Square Value Prob > F 
 
Model 160.83 2 80.42 67.33 < 0.0001 Significant 
A-Stabilizer concentration 48.17 1 48.17 40.33 0.0007 
 
B-Speed 112.67 1 112.67 94.33 < 0.0001 
 
Residual 7.17 6 1.19 
   
Cor Total 168.00 8 
    
 
 
 
(a) (b) 
 
Figure 4: Response Surface Plot (a) Stabilizer Concentration and (b) Speed on Entrapment Efficacy (Y1) 
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(a) (b) 
Figure5:  3D Surface Plot: (a) stabilizer Concentration and (b) Speed on Entrapment Efficacy (Y1) 
 
3.14 Effect on % Drug release (Y2) - Surface Response 
Study 
Positive value for coefficient of X1- type of 
stabilizer Concentration in equation indicates increase in 
Drug release. Positive value of coefficient of X2-Speed 
also indicates increase in response of Y2 i.e. % CDR. It 
indicates linearity of surface response and contour plot as 
shown in figure. 
 
Y=+87.67+2.33* A+3.50* B 
 
Table: 2ANOVA Table for Response Y2 (%CDR) 
ANOVA for Response Surface Linear model 
Analysis of variance table [Partial sum of squares - Type III] 
 
Sum of 
 
Mean F p-value 
 
Source Squares Df Square Value Prob > F 
 
Model 106.17 2 53.08 83.09 < 0.0001 significant 
A-Stabilizer concentration 32.67 1 32.67 51.13 0.0004 
 
B-Speed 73.50 1 73.50 115.04 < 0.0001 
 
Residual 3.83 6 0.64 
   
Cor Total 110.00 8 
    
 
 
 
(a) (b) 
Figure: 6 Response Surface Plot: (a) Speed (b) Stabilizer Concentration on % CDR (Y2) 
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(a) (b) 
Figure 7: 3D Surface Plot: (a) Stabilizer Concentration and (b) Speed on % CDR (Y2) 
 
3.15 Establishing Design Space and Control Strategy 
 
Figure: 8 FDS Graph 
 
FDS bend demonstrates what % part of outline 
space has given expectation mistake or lower. Great 
configuration will have compliment and lower bend than 
poor outline as appeared in figure. Compliment implies 
general forecast mistake will be consistent. Lower implies 
general forecast .blunder will be littler. FDS ought to be no 
less than 0.8 or 80% for investigation, and 100% for 
strength testing.  
3.16 Validation 
From polynomial mathematical statements created 
for reaction, serious network and incorporated inspect was 
performed over test field utilizing Design Expert Software 
(9.0.2.0.). During free variable portrayal study, effect of 
parameters Stabilizer Concentration (mg) and Speed 
(RPM) were surveyed. Criteria considered of reaction E.E 
(Y1), Drug discharge (Y2), between, 80-90 %, and 85-95 
% separately. This study lead to information space and at 
last plan space from multidimensional mix of force, 
dissolvable volume and time prompts satisfactory working 
reaches for confining adhesive as for target item profile. 
Plan space appeared in figure likewise called as overlay 
plot which is shaded locale with yellow shading shows that 
district of effective working extents. 
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Figure 9: Overlay Plot 
 
Figure 10: Overlay Plot 
3.17 Check point analysis of Validation Batches 
ANS10 & ANS11 formulation was made for check point analysis and predicted and experimental values were 
compared. 
Table 17: Validation of Batches ACNS10 & ACNS11: Predicted Response 
Batch No Stabilizer Concentration (X1) Speed-RPM (X2) % E.E (Y1) % CDR (Y2) 
ACNS10 3.9 1950 85.45 92.91 
ACNS11 3.81 1923 84.96 92.52 
 
Table: 18 Validation Batches ACNS10& ACNS11: Actual Response 
Batch No Stabilizer Concentration (X1) Speed-RPM (X2) % E.E (Y1) % CDR (Y2) 
ACNS10 3.9 1950 84.26±1.22 91.84±1.54 
ACNS11 3.81 1923 83.76±1.32 91.37±1.04 
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3.18 Particle size Analysis of Optimized Batch ACNS10 
 
Figure 11: Particle size Analysis of Optimized Batch ACNS10 
 
Pure Aceclofenac used for study was characterized by relatively large particles as reported. nanosuspension 
prepared after emulsification and solvent evaporation may decrease in particle size when compared to pure drug particles 
which may have positive effect on drug dissolution rate As per Noyes-Whitney equation. Hence decrease in particle size 
will have significant effect in drug solubility and dissolution characteristics. 
 
3.19 Zeta potential of optimised Batch ACNS10 
 
Figure: 12 Zeta potential of optimis-ed Batch ACNS10 
Zeta potential was determined by Beckman coulter. Zeta potential of selected formulation (ANS10) was found to 
be + 5.65. Positive zeta value was obtained due to positive charge of polymer. Mobility distribution graph can be given in 
Figure. 
 
3.20 Stability Study of ACNS 10 for 1 Month 
Table: 19 Stability Study of ACNS 10 for 1 Month 
Parameter 
Optimized Aceclofenac Nanosuspension 
Room Temperature 
0 Day 10 Day 20 Day 30 Day 
% E.E 84.26 83.48 84.21 84.91 
% CDR 91.84 90.43 91.68 90.57 
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Comparison study of Nanosuspension optimized formulation and marketed formulation of Aceclofenac Tablets 
Table 20: In-Vitro Drug release study 
Time 
(min) 
% Drug Release 
Marketed Aceclofenac tablet  
(Mean± S.D.) (n=3) 
ACNS10 (Mean± S.D.) 
(n=3) 
ACNS11 (Mean± S.D.) 
(n=3) 
0 0.00 0.00 0.00 
5 7.77±2.12 20.42±2.12 24.88±1.52 
10 13.40±1.54 30.92±2.58 41.16±1.25 
15 17.30±1.46 50.78±1.97 54.95±1.47 
20 23.64±2.28 58.49±2.28 64.37±1.28 
25 33.73±1.18 77.25±2.43 76.03±1.34 
30 46.03±2.17 91.87±2.62 92.12±1.92 
 
From comparison study of Nanosuspension 
optimized formulation and market formulation of 
Aceclofenac Tablets, It can be concluded that% Drug 
release of Aceclofenac Nanosuspension was better than 
marketed formulation of Aceclofenac Tablets (Aerosol 
Tablet).  
 
4. Conclusion 
Nanosuspension containing Aceclofenac was 
prepared by quasi emulsion Solvent Evaporation method 
using Pluronic F68 using DoE approach. Optimized Batch 
was subjected for % drug content, % Entrapment 
efficiency; Particle size Analysis, and in vitro drug release 
studies, low SD and CV values indicate drug content was 
uniform and reproducible in all formulations. 
IR spectral analysis and DSC suggested 
compatibility between drug and formulation additive. Drug 
exists in original form and available for biological action. 
Dissolution parameters were studied by using 
dissolution software PCP DISSO V.3 for Nanosuspension 
which proved increase in Saturation Solubility and 
Dissolution rate. 
Nanosuspension which gave better physical, 
morphological and % encapsulation in either of Stabilizers 
and Excipients. Various Oral formulations with 
Aceclofenac in free form and in Nanoparticulate delivery 
system were formulated and in vitro release studies were 
carried out. 
By considering all results of Check Point Analysis 
Nanosuspension It shows that saturation solubility of 
Nanosuspension is increased up to two to three folds as 
compared to pure Aceclofenac. Also dissolution rate is 
increase therefore bioavailability of Aceclofenac is 
increases. No changes found after stability analysis for 
period of 1 month. 
From study it can be concluded that it is possible to design 
Nanosuspension for Aceclofenac may increase efficacy and 
patient compliance which are of prime importance. 
 
Future Perspective 
Aceclofenac loaded Nanosuspension based oral 
drug delivery system may be less side effect with reduction 
of dose by immediate release at system. Aceclofenac 
Nanosuspension can be enhance solubility and dissolution 
and increase bioavailability & hence increase patient 
Compliance. 
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